Page 949 - Clinical Small Animal Internal Medicine
P. 949

887


  VetBooks.ir






               89


               Feline Viral Upper Respiratory Tract Disease
               Yvonne Drechsler, PhD

               College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA, USA



                 Etiology/Pathophysiology                           Epidemiology

               Feline viral infectious upper respiratory tract disease   Infection with both FHV‐1 and FCV is widespread in the
               is primarily caused by two viruses: feline herpesvirus   general cat population. The prevalence of infection and
               (FHV‐1) and feline calicivirus (FCV). Infection is com-  clinical disease is higher in multicat households, colo-
               mon in multicat environments, and most cats have   nies, catteries or shelters. Viral reactivation may occur in
               been exposed. FHV‐1 is an enveloped single‐stranded   latently infected cats when they are stressed or if their
               DNA virus belonging to the alpha‐herpesvirus family.   immune system is compromised. FHV‐1 is short‐lived in
               As such, the virus exists in a latent form in the trigemi-  the environment, and transmission occurs mainly by
               nal ganglia after initial infection and can be reacti-  direct contact with an infected cat. However, transmis-
               vated by stressors. This leads to shedding via secretions   sion through fomites in crowded environments is also
               from oral, nasal, and conjunctival membranes. Viral   important.
               replication is usually restricted to the upper respira-  Cats infected with FCV may be carriers who shed virus
               tory tract, due to viral preference for lower tempera-  while appearing clinically healthy. Virus may be shed in
               tures. However,  in young kittens  and  possibly   the urine and feces in addition to respiratory secretions.
               immunosuppressed cats, more severe systemic disease   FCV survives in the environment much longer than
               can occur.                                         FHV‐1 and is resistant to quaternary ammonium com-
                 Feline calicivirus belongs to the Caliciviridae family,   pounds. Therefore, in addition to direct and aerosol con-
               and consists of a single‐stranded positive RNA genome.   tact  with  respiratory  secretions,  fomites  are  a  very
               This genome structure has a high mutation rate and   important means of transmission for FCV.
               therefore the isolates are highly variable. Strains can vary
               in their pathogenicity. Like FHV‐1, transmission occurs
               via secretions from oral, nasal, and conjunctival mem-    Signalment
               branes. FCV persists in tonsillar and other oropharyn-
               geal tissues, leading to a carrier state, but the mechanism   Cats of any sex and age can develop respiratory disease
               of persistence is not well understood. In addition to   caused by FHV‐1 or FCV, with kittens being more
               causing upper respiratory disease, FCV can be associ-  susceptible.
               ated with lameness due to acute synovitis, possibly due
               to antigen‐activated macrophages residing in the syno-
               vial membrane. Rarely, FCV can cause virulent systemic     History and Clinical Signs
               disease (VSD). Lesions associated with VSD are severe
               and include oral and dermal ulcerations, bronchointer-  Cats from multicat households, colonies, catteries
               stitial pneumonia, necrosis of the liver, spleen and pan-  or shelters are commonly infected. A history of stress
               creas, and death. The pathogenesis of VSD is not fully   or immune suppression may be noted. FHV‐1 may
               understood.                                        cause  severe respiratory disease, especially in




               Clinical Small Animal Internal Medicine Volume II, First Edition. Edited by David S. Bruyette.
               © 2020 John Wiley & Sons, Inc. Published 2020 by John Wiley & Sons, Inc.
               Companion website: www.wiley.com/go/bruyette/clinical
   944   945   946   947   948   949   950   951   952   953   954